A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Fesoterodine Flexible Dose Regimen in Patients With Overactive Bladder

Trial Profile

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Fesoterodine Flexible Dose Regimen in Patients With Overactive Bladder

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2010

At a glance

  • Drugs Fesoterodine (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Jan 2010 Results have been published in Urology.
    • 03 Oct 2009 Results were presented at the 39th Annual Meeting of the International Continence Society.
    • 03 Sep 2008 Status changed from recruiting to completed, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top